XBIO
HEALTHCAREXenetic Biosciences Inc
$3.17+0.08 (+2.59%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving XBIO Today?
No stock-specific AI insight has been generated for XBIO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.90$13.93
$3.17
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-1.58
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-0.9%
Debt / Equity—
Trading
Volume15K
Avg Volume (10D)—
Shares Outstanding2.3M
XBIO News
17 articles- Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual MeetingYahoo Finance·Apr 22, 2026
- Xenetic Biosciences, Inc. Reports Full Year 2025 Financial ResultsYahoo Finance·Mar 13, 2026
- Xenetic Biosciences: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual MeetingYahoo Finance·Dec 11, 2025
- Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase PlatformYahoo Finance·Nov 19, 2025
- Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 13, 2025
- Xenetic Biosciences: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue EstimatesYahoo Finance·Oct 30, 2025
- Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common StockYahoo Finance·Oct 10, 2025
- Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 13, 2025
- Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue EstimatesYahoo Finance·Aug 12, 2025
- Xenetic Biosciences: Q2 Earnings SnapshotYahoo Finance·Aug 12, 2025
- Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaYahoo Finance·Jul 30, 2025
- Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformYahoo Finance·Jul 23, 2025
- Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic CancerYahoo Finance·Jul 8, 2025
- Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·May 14, 2025
- Xenetic Biosciences: Q1 Earnings SnapshotYahoo Finance·May 13, 2025
All 17 articles loaded
Price Data
Open$2.95
Previous Close$3.09
Day High$2.98
Day Low$2.95
52 Week High$13.93
52 Week Low$1.90
52-Week Range
$1.90$13.93
$3.17
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-1.58
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-0.9%
Debt / Equity—
Trading
Volume15K
Avg Volume (10D)—
Shares Outstanding2.3M
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—